Back to results
US 2017/0304247 A1Published application
Eicosapentaenoic acid (epa) formulations
AssigneeQualitas Health, Ltd.
InventorsBrian J. WAIBEL, Hans SCHONEMANN, Val KRUKONIS, Michael KAGAN
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions comprising eicosapentaenoic acid (EPA) and polar lipids (e.g., glycolipids and phospholipids), and which do not contain any docosahexaenoic acid (DHA) or esterified fatty acids.
Claims32
An EPA composition comprising from about 15 wt. % to about 90 wt. % eicosapentaenoic acid (EPA) and about 10 wt. % to about 70 wt. % polar lipids, wherein:
- the polar lipids comprise phospholipid conjugates and glycolipid conjugates;
- about 3 wt. % to about 50 wt. % of the EPA in the composition is a phospholipid conjugate;
- about 5 wt. % to about 50 wt. % of the EPA in the composition is a glycolipid conjugate;
- about 0 wt. % to about 10 wt. % of the EPA is a triglyceride conjugate or a diglyceride conjugate;
- and
- the composition does not comprise docosahexaenoic acid (DHA) or methyl esters or ethyl esters, and wherein the composition is suitable for human consumption.
3 more elements
2-4. (canceled)
6-9. (canceled)
An EPA composition comprising following distribution of EPA by lipid class:
- about 3 wt. % to about 50 wt. % of the EPA is a phospholipid conjugate;
- about 5 wt. % to about 50 wt. % of the EPA is a glycolipid conjugate;
- about 0 wt. % to about 10 wt. % of the EPA is a triglyceride conjugate or a diglyceride conjugate;
- and
- about 15 wt. % to about 85 wt. % of the EPA is in free fatty acid form, wherein the composition does not comprise methyl esters or ethyl esters, and wherein the composition is suitable for human consumption.
2 more elements
(canceled)
(canceled)
37-65. (canceled)
Dependencies are inferred from the claim text.